It is with great sadness that I share the news that our colleague, Gavril Pasternak, passed away on Friday, February 22, 2019, after a brief battle with illness. He was surrounded by his family and friends. Always a class act, his only concern was that his lab members be looked after following his passing. He was an exceptional scientist, colleague, and friend.Gav completed his BS in Chemistry at Johns Hopkins University and continued onto MD-PhD training, a Fellowship, Internship, and Residency, all at Hopkins. In his graduate work with Solomon Snyder, he carried out seminal studies characterizing the first opioid receptor and contributed to the discovery of the endogenous enkephalin ligands. He joined the faculty at MSK in 1979 as a laboratory head in the Sloan Kettering Institute and a neurologist in Memorial Hospital. Here, his research focused on defining and understanding novel targets of opioid action, and included the development of new analgesics with reduced side effects. He published over 400 papers during his career and trained numerous graduate students and postdoctoral fellows. He was also a generous and thoughtful mentor to his junior faculty colleagues. An avid lacrosse player, he won three national championships at Hopkins and also founded New York City’s first youth lacrosse program in 1996.
The Pharmacologist, ASPET's quarterly news magazine tribute to Dr. Gavril Pasternak. click here: g_pasternak_aspet.pdf
The staff of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College note with sadness the untimely death of our esteemed colleague David Y. Gin, a brilliant and talented chemist who joined the Sloan-Kettering Institute's Molecular Pharmacology and Chemistry Program in 2006. Dr. Gin was working at the nexus of synthetic chemistry, clinical trials, and research to develop new, safer, and more-potent immunological and therapeutic agents for cancer and infectious diseases. He was a gentle, kind, good-humored, and remarkable human being who will be sorely missed. We extend our deepest condolences to his wife, Mary; his children, Duncan and Laura; and his entire family. David A. Scheinberg, MD, PhD Chair, Molecular Pharmacology and Chemistry Program Thomas J. Kelly, MD, PhD Director, Sloan-Kettering Institute Craig B. Thompson, MD President & CEO, Memorial Sloan-Kettering Cancer Center.
DR. ARTHUR HULL HAYES, JR. FORMER FDA COMMISSIONER, DIES at 76. Dr. Arthur Hull Hayes, Jr. who led the US Food and Drug Administration during the Tylenol crisis of 1982 and was a nationally known professor of clinical pharmacology, died on February 11, 2010 from complications caused by a chronic illness. In 1981, Dr. Hayes was appointed Commissioner of the Food and Drug Administration by President Ronald Reagan. During his years at the agency, he directed the FDA''s response to the Tylenol tampering cases, called for a voluntary moratorium on direct-to-consumer advertising of prescription medicines and weathered criticism on the FDA''s approval of the sweetener aspartame. Born in Highland Park, Michigan in 1933 to Arthur Hull Hayes and Florence (Gruber) Hayes, he loved to travel and visited countries on five continents with his wife of 49 years. In 1970, he and his wife co-founded a medical clinic on the Pacific island of Pohnpei, and they worked as a doctor and nurse team on behalf of the Jesuit Missions. Hayes was ordained a permanent deacon in the Roman Catholic Church in 1978 and served in parishes in Pennsylvania, Maryland and New York. Dr. Hayes received his A.B. in philosophy magna cum laude from Santa Clara University in 1955 and then went to Oxford University as a Rhodes Scholar, earning a degree in philosophy, politics and economics in 1957. He returned to the US to study medicine; first at Georgetown University Medical School and graduated from Cornell University Medical School in 1964. Following his graduation, he served in the United States Army Medical Corps from 1965 to 1967-achieving the rank of Captain. Dr. Hayes worked as an Assistant Professor of medicine and pharmacology and Associate Dean for Academic Programs at Cornell before becoming a Professor of Medicine and Pharmacology and Director of Clinical Pharmacology at Pennsylvania State University Medical School in Hershey, Pennsylvania. After leaving the FDA, Dr. Hayes worked as Provost and Dean at New York Medical College and later, in 1986, was appointed President of E.M. Pharmaceuticals, a division of the German company E. Merck. Five years later, he founded MediScience Associates, a consulting firm, part of Nelson Communications, Inc., and stayed there until 2005, when he retired. Dr. Hayes served on numerous commercial and pro bono boards, received many honorary degrees and awards and was named a visiting professor at a several academic institutions. He consulted for a dozen foreign governments, authored more than a hundred professional papers, delivered thousands of lectures and trained many clinical pharmacologists working today.